<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db00198 DrugCentral: oseltamivir Synonymous :(−)-oseltamivir | 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))- | ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate | oseltamivir | oséltamivir | oseltamivirum 
Drug Sentece Context Table 1.">

  
  <link rel="alternate" hreflang="en-us" href="https://bio-hub.github.io/drugpanel/oseltamivir/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://bio-hub.github.io/drugpanel/oseltamivir/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://bio-hub.github.io/drugpanel/oseltamivir/info/">
  <meta property="og:title" content="OSELTAMIVIR | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db00198 DrugCentral: oseltamivir Synonymous :(−)-oseltamivir | 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))- | ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate | oseltamivir | oséltamivir | oseltamivirum 
Drug Sentece Context Table 1."><meta property="og:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>OSELTAMIVIR | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">OSELTAMIVIR</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db00198' target='_blank'>db00198</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=oseltamivir" target="_blank">oseltamivir</a> <br>
Synonymous :(−)-oseltamivir | 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))- | ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate | oseltamivir | oséltamivir | oseltamivirum
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>oseltamivir</em> gene in 105 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/32023685" target="_blank">32023685</a>
</td>
<td style="text-align:center;">
Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32031570" target="_blank">32031570</a>
</td>
<td style="text-align:center;">
Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32040667" target="_blank">32040667</a>
</td>
<td style="text-align:center;">
Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32164080" target="_blank">32164080</a>
</td>
<td style="text-align:center;">
Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32196707" target="_blank">32196707</a>
</td>
<td style="text-align:center;">
All patients were given antiviral therapy (including oseltamivir), oxygen inhalation, and antibiotics.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32256547" target="_blank">32256547</a>
</td>
<td style="text-align:center;">
We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). […] Se identificaron 24 ensayos clínicos relacionados con más de 20 medicamentos, como inmunoglobulina humana, interferones, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumab y medicina tradicional china. […] Foram identificados 24 ensaios clínicos envolvendo mais de 20 medicamentos, tais como imunoglobulina humana, interferons, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumabe e medicamentos chineses tradicionais.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32281114" target="_blank">32281114</a>
</td>
<td style="text-align:center;">
Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32282022" target="_blank">32282022</a>
</td>
<td style="text-align:center;">
Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32297571" target="_blank">32297571</a>
</td>
<td style="text-align:center;">
In particular, several cases of recovered patients havebeen reported after being treated with lopinavir/ritonavir (which is widely used to treat humanimmunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32330277" target="_blank">32330277</a>
</td>
<td style="text-align:center;">
The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32339248" target="_blank">32339248</a>
</td>
<td style="text-align:center;">
The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32348232" target="_blank">32348232</a>
</td>
<td style="text-align:center;">
The patient was hospitalized and treated with Oseltamivir 75 mg every 12 hours, Lopinavir/Ritonavir (Kaletra) 400/100 mg every 12 hours and hydroxychloroquine 400 mg stat.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32364041" target="_blank">32364041</a>
</td>
<td style="text-align:center;">
The covalent docking showed that saquinavir, ritonavir, remdesivir, delavirdine, cefuroxime axetil, oseltamivir and prevacid have the highest binding energies MMGBSA of -72.17, -72.02, -65.19, -57.65, -54.25, -51.8, and -51.14 kcal/mol, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32371416" target="_blank">32371416</a>
</td>
<td style="text-align:center;">
Following treatment with oseltamivir and short-term methylprednisolone combined with symptomatic management, all three patients recovered within 3 weeks, as evidenced by the disappearance of their symptoms, clearance of pulmonary infiltrates and consecutive negative molecular diagnostic test findings.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32373997" target="_blank">32373997</a>
</td>
<td style="text-align:center;">
No sufficient results have been reached by the use of interferon (IFN), lopinavir/ritonavir, orbidol, and oseltamivir in the treatment of the coronaviruses infection.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32375574" target="_blank">32375574</a>
</td>
<td style="text-align:center;">
Moreover, it was also observed that chloroquine has appreciable binding affinities for 3-Chymotrpsin- like protease and cyclic AMP-dependent protein kinase A when compared to Oseltamivir and ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32394467" target="_blank">32394467</a>
</td>
<td style="text-align:center;">
Neuraminidase inhibitors such as oseltamivir, peramivir, and zanamivir are invalid for 2019-nCoV and are not recommended for treatment but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the progression of MERS-CoV disease and can be useful for patients of COVID-19 and, in combination with Arbidol, has a direct antiviral effect on early replication of SARS-CoV.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32395418" target="_blank">32395418</a>
</td>
<td style="text-align:center;">
These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405418" target="_blank">32405418</a>
</td>
<td style="text-align:center;">
None of the infected nurses were hospitalized and all of them preferred to be quarantine at home and receive the necessary care and treatment (Oseltamivir, Azithromycin and Kaletra.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405421" target="_blank">32405421</a>
</td>
<td style="text-align:center;">
Comparator drugs were oseltamivir, umifenovir, lopinavir/ritonavir or placebo.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32405454" target="_blank">32405454</a>
</td>
<td style="text-align:center;">
Lopinavir/ritonavir (200mg/50mg) two tablet tow times, Ribavirin 200mg every six hours, and Oseltamivir 75mg tow times were given for the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32409433" target="_blank">32409433</a>
</td>
<td style="text-align:center;">
Antivirals to treat influenza (oseltamivir) have limited activity against SARS-CoV-2, but favipiravir and umifenovir, two influenza antivirals available internationally, may have distinct viral targets and require further investigation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32411770" target="_blank">32411770</a>
</td>
<td style="text-align:center;">
All patients received combined antiviral treatment on admission, including β-interferon, lopinavir/tonavir, Abidol and oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32460369" target="_blank">32460369</a>
</td>
<td style="text-align:center;">
In addition, it was found that clarithromycin, naproxen and oseltamivir combination leads to decrease in mortality rate and duration of hospitalization in patients with pneumonia due to influenza.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32476080" target="_blank">32476080</a>
</td>
<td style="text-align:center;">
The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with heparin, hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32487990" target="_blank">32487990</a>
</td>
<td style="text-align:center;">
Baloxavir, the recently approved influenza antiviral, inhibits initiation of viral mRNA synthesis, whereas oseltamivir, an older drug, inhibits release of virus progeny. […] Baloxavir blocks virus replication more rapidly and completely than oseltamivir, reducing the duration of infectiousness.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32548163" target="_blank">32548163</a>
</td>
<td style="text-align:center;">
On January 22, oseltamivir phosphate capsules were given orally (75 mg, twice daily) for 6 d.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32556649" target="_blank">32556649</a>
</td>
<td style="text-align:center;">
His respiratory function deteriorated despite treatments with lopinavir/ritonavir, oseltamivir, azithromycin and meropenem at a regional hospital.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32562159" target="_blank">32562159</a>
</td>
<td style="text-align:center;">
According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32566561" target="_blank">32566561</a>
</td>
<td style="text-align:center;">
For adults with SARS, interferon was associated with reduced corticosteroid dose [weighted mean difference (WMD) = -0.14 g; 95% CI, -0.21 to -0.07] but had no effect on mortality (RR =0.72; 95% CI, 0.28 to 1.88); ribavirin did not reduce mortality (RR =0.68; 95% CI, 0.43 to 1.06) and was associated with high risk of severe adverse reactions; and oseltamivir had no effect on mortality (RR =0.87; 95% CI, 0.55 to 1.38).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32571773" target="_blank">32571773</a>
</td>
<td style="text-align:center;">
Patients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir. […] To determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2). […] Patients aged ≥1 year presenting to primary care with influenza-like illness (ILI), and who tested positive for coronavirus (not including SARS-CoV-2), were randomised to usual care or usual care plus oseltamivir. […] Coronaviruses (CoV-229E, CoV-OC43, CoV-KU1 and CoV-NL63) were identified in 308 (9%) out of 3266 randomised participants in the trial; 153 of these were allocated to usual care and 155 to usual care plus oseltamivir; the primary outcome was ascertained in 136 and 147 participants, respectively. […] The median time to recovery was shorter in patients randomised to oseltamivir: 4 days (interquartile range [IQR] 3-6) versus 5 days (IQR 3-8; hazard ratio 1.31; 95% confidence interval = 1.03 to 1.66; <i>P</i> = 0.026). […] Primary care patients with ILI testing positive for coronavirus (not including SARS-CoV-2) recovered sooner when oseltamivir was added to usual care compared with usual care alone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32574328" target="_blank">32574328</a>
</td>
<td style="text-align:center;">
The most commonly used antiviral treatment modalities included, lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor). <b>Conclusions:</b> Development of ARDS may play a role in estimating disease progression and mortality risk.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32591667" target="_blank">32591667</a>
</td>
<td style="text-align:center;">
Additionally, this study suggested oseltamivir, iopinavir, remdesivir, chloroquine, baricitinib, ruxolitinib, and fedratinib as possible drugs to help manage COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32593339" target="_blank">32593339</a>
</td>
<td style="text-align:center;">
The most frequently used drug with antiviral activity was hydroxychloroquine (40 [7%] patients), followed by remdesivir (17 [3%] patients), lopinavir-ritonavir (six [1%] patients), and oseltamivir (three [1%] patients).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32602678" target="_blank">32602678</a>
</td>
<td style="text-align:center;">
Oseltamivir and chloroquine were given to all 26 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32603692" target="_blank">32603692</a>
</td>
<td style="text-align:center;">
In contrast, oseltamivir was not effective and corticosteroids are not currently recommended.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32655019" target="_blank">32655019</a>
</td>
<td style="text-align:center;">
Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32659126" target="_blank">32659126</a>
</td>
<td style="text-align:center;">
Dose modification/avoidance should be considered for chloroquine, atazanavir, oseltamivir, ribavirin, anakinra, and Janus associated kinase inhibitors in patients with organ function impairment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32667444" target="_blank">32667444</a>
</td>
<td style="text-align:center;">
Antibiotics and oseltamivir should only be considered for patients with suspected bacterial or influenza coinfection, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32670273" target="_blank">32670273</a>
</td>
<td style="text-align:center;">
Recently, it was shown that the treatment with sphingosine-1-phosphate receptor 1 analog, CYM5442, resulted in the significant dampening of the immune response upon H1N1 challenge in mice and improved survival of H1N1 infected mice in combination with an antiviral drug, oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32721449" target="_blank">32721449</a>
</td>
<td style="text-align:center;">
Researchers from Thailand explored the use of combination of anti-influenza drugs such as Oseltamivir, Lopinavir and Ritonavir to treat it.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32735768" target="_blank">32735768</a>
</td>
<td style="text-align:center;">
Supportive care and management of the complications that are caused mainly by inflammation might be the key to greater survival rates and shorter hospitalization (e.g., the use of remdesivir, lopinavir, ritonavir, umifenovir (arbidol), oseltamivir, ganciclovir, favipiravir, darunavir, hydroxychloroquine, chloroquine, colchicine, azithromycin, anakinra, canakinumab, tocilizumab, siltuximab, sarilumab, Type 1 interferon, interferon β-1a, interferon α- 2b, baricitinib, ruxolitinib, fedratinib, methylprednisolone and dexamethasone).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32737627" target="_blank">32737627</a>
</td>
<td style="text-align:center;">
Administration of antiviral drugs especially oseltamivir or ganciclovir is associated with a decreased risk of death in severe patients (OR 0.17, 95% CI 0.05-0.64, p &lt; 0.001). […] Administration of oseltamivir or ganciclovir might be beneficial for reducing mortality in severe patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32745502" target="_blank">32745502</a>
</td>
<td style="text-align:center;">
The predicted top 3 antiviral drugs against SARS-CoV-2 are remdesivir, oseltamivir, and zanamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32750201" target="_blank">32750201</a>
</td>
<td style="text-align:center;">
Time from onset to admission (HR = 0.829, P &lt; 0.001), and administration of corticosteroid (HR = 0.496, P = 0.002), arbidol (HR = 2.605, P = 0.008) and oseltamivir (HR = 0.416, P &lt; 0.001) were independently associated with duration of viral shedding. […] Treatment should be started as early as possible, but corticosteroid and oseltamivir should be initiated with caution.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32754388" target="_blank">32754388</a>
</td>
<td style="text-align:center;">
In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32758569" target="_blank">32758569</a>
</td>
<td style="text-align:center;">
The docking was done with most discussed drugs for SARS-CoV-2 like Ritonavir, Lopinavir, Remdesivir, Chloroquine, Hydroxychloroquine (HCQ), routine antiviral drugs like Oseltamivir and Ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32768505" target="_blank">32768505</a>
</td>
<td style="text-align:center;">
These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other miscellaneous agents.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32771032" target="_blank">32771032</a>
</td>
<td style="text-align:center;">
To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes). […] There will be a total of seven comparator groups: Each drug (Hydroxychloroquine Phosphate/Sulfate, Oseltamivir and Azithromycin) given as monotherapy (three groups); combinations of each of two drugs (three groups); and a final group on triple drug regimen.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32777318" target="_blank">32777318</a>
</td>
<td style="text-align:center;">
The skin reactions of antimalarials (chloroquine and hydroxychloroquine), antivirals (lopinavir/ritonavir, ribavirin with or without interferon, oseltamivir, remdesivir, favipiravir, and darunavir), and treatments for complications (imatinib, tocilizumab, anakinra, immunoglobulins, corticosteroids, colchicine and low molecular weight heparins) are analyzed.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32781034" target="_blank">32781034</a>
</td>
<td style="text-align:center;">
Invasive mechanical ventilation was used in 18% (median 7.5 days); antibiotics, oseltamivir, and corticosteroids were used in 76%, 43%, and 23%, respectively, but not hydroxychloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32813760" target="_blank">32813760</a>
</td>
<td style="text-align:center;">
Regarding clinical treatment, the most often used medicines were intravenous antibiotics (84.7%), chloroquine (45.8%) and oseltamivir (31.9%).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32827400" target="_blank">32827400</a>
</td>
<td style="text-align:center;">
Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32831522" target="_blank">32831522</a>
</td>
<td style="text-align:center;">
Therefore, it is of interest to document the molecular docking analysis data of 32 N-substituted Oseltamivir derivatives inhibitors of influenza virus H5N1 with the Novel Coronavirus main protease (2019-nCoV). […] We describe the optimal binding features of Oseltamivir derivatives with the SARS-Cov-2 main protease (Code PDB: 6LU7) for further consideration.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32832735" target="_blank">32832735</a>
</td>
<td style="text-align:center;">
The patient was diagnosed with COVID-19 a day prior and home isolation was recommended with hydroxychloroquine and oseltamivir P.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32838264" target="_blank">32838264</a>
</td>
<td style="text-align:center;">
There are also pregnancy safety and placental transfer data for colchicine, steroids, oseltamivir, azithromycin, and some monoclonal antibodies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32842015" target="_blank">32842015</a>
</td>
<td style="text-align:center;">
The effects of the empirical use of oseltamivir were also analyzed in both groups. […] Notably, in the IAV-positive group, patients who received oseltamivir had a significantly lower fatality rate (0 vs. […] 36.84%, P = 0.025) compared with those not receiving oseltamivir. […] Prospective studies with larger sample sizes are needed to clarify whether IAV increases the fatality rate of COVID-19 and to elucidate any benefits of empirical usage of oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32848446" target="_blank">32848446</a>
</td>
<td style="text-align:center;">
Antiviral medication (lopinavir, darunavir, favipiravir, remdesivir, ribavirin, oseltamivir, tocilizumab, and umifenovir), ACE inhibitors, interferon-α2b, co-therapy with azithromycin, inhaling iNO, and oxygen therapy can be used for treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32876224" target="_blank">32876224</a>
</td>
<td style="text-align:center;">
The therapeutic agents evaluated were chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, oseltamivir, interferon, atazanavir and anti SARS-CoV-2 serum.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32922095" target="_blank">32922095</a>
</td>
<td style="text-align:center;">
The share of baloxavir was 15%, while the shares of oseltamivir and laninamivir were 42% and 31%, respectively in the 2018-2019 season. […] However, in the 2019-20 season, the share of baloxavir and laninamivir was reduced to 3% and 17%, respectively, in contrast to an increase in the share of oseltamivir (66%).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32927129" target="_blank">32927129</a>
</td>
<td style="text-align:center;">
Oseltamivir is a first-line antiviral drug, especially in primary hospitals. […] During the ongoing outbreak of coronavirus disease 2019 (COVID-19), most patients with COVID-19 who are symptomatic have used oseltamivir. […] Considering its popular and important role as an antiviral drug, it is necessary to evaluate oseltamivir in the treatment of COVID-19. […] To evaluate the effect of oseltamivir against COVID-19. […] Molecular docking was used to analyze the theoretical possibility of effective binding of oseltamivir with the active centers of the viral proteins. […] In vitro study was used to evaluate the antiviral efficiency of oseltamivir against SARS-CoV-2. […] By clinical case analysis, we statistically evaluated whether the history of oseltamivir use influenced the progression of the disease. […] Through an analysis of molecular docking, we discovered that oseltamivir carboxylic acid was more favorable to bind to the active site of 3CLpro effectively, but its inhibitory effect was not strong compared with the positive group. […] We found that oseltamivir is ineffective against SARS-CoV-2 in vitro study and the clinical use of oseltamivir did not improve the patients’ symptoms and signs and did not slow the disease progression. […] We consider that oseltamivir isn’t suitable for the treatment of COVID-19. […] During the outbreak of novel coronavirus, when oseltamivir is not effective for the patients after they take it, health workers should be highly vigilant about the possibility of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32954046" target="_blank">32954046</a>
</td>
<td style="text-align:center;">
The patient was treated with Oseltamivir 75mg and clarithromycin 500 mg (12 hourly for each respectively) for 10 days with paracetamol.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32991900" target="_blank">32991900</a>
</td>
<td style="text-align:center;">
Antiviral drugs, such as remdesivir, ritonavir, oseltamivir, darunavir, lopinavir, zanamivir, peramivir, and oseltamivir, have also been tested as treatments for COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32997237" target="_blank">32997237</a>
</td>
<td style="text-align:center;">
The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33017386" target="_blank">33017386</a>
</td>
<td style="text-align:center;">
Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33023552" target="_blank">33023552</a>
</td>
<td style="text-align:center;">
On day 4 of admission, with suspicion of COVID-19, hydroxychloroquine, lopinavir/ritonavir and oseltamivir were added to the antibiotic regimen.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33029696" target="_blank">33029696</a>
</td>
<td style="text-align:center;">
The repurposed drugs like Chloroquine and Hydroxychloroquine, Tenofovir, Remdesivir, Ribavirin, Darunavir, Oseltamivir, Arbidol (Umifenovir), Favipiravir, Anakinra, and Baricitinib are already being used in clinical trials to treat the COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33043651" target="_blank">33043651</a>
</td>
<td style="text-align:center;">
All the patients received antiviral treatment, either lopinavir/ritonavir or oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33064680" target="_blank">33064680</a>
</td>
<td style="text-align:center;">
E1KC4 and camostat mesylate are potential inhibitors of SARS-CoV-2 S protein, achieving an effect similar to oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33073355" target="_blank">33073355</a>
</td>
<td style="text-align:center;">
Ideally, there would be an oral antiviral agent available such as seen with the use of oseltamivir phosphate for influenza.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33081849" target="_blank">33081849</a>
</td>
<td style="text-align:center;">
) Standard Treatment for non-severe cases (STNS): Strict Isolation, Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask), Hydration, Proper Nutrition, Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant), Treatment of Comorbid Diseases, Oseltamivir (75 mg BD) for patients who are tested positive for H1N1. […] Standard Treatment for severe patients (STs): Strict Isolation, Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask), Fluid Therapy, Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant), Oxygen supplementation (As required), Invasive ventilation (As required), Antibiotic agents for other associated infections (according to 2019 ATS/IDSA guidelines for non-ICU and ICU patients), Vasopressor support, Renal-replacement therapy, Treatment of Comorbid Diseases, Oseltamivir (75 mg BD) for patients who are tested positive for H1N1.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33107292" target="_blank">33107292</a>
</td>
<td style="text-align:center;">
Oseltamivir was started in one (2.3%) patient, and 10 (24.7%) patients were treated with hydroxychloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33116663" target="_blank">33116663</a>
</td>
<td style="text-align:center;">
All patients received antiviral treatment (arbidol, oseltamivir, and ribavirin); 78.4% of patients received antibiotic therapy (moxifloxacin, levofloxacin, and cefdinir); patients in the moderate disease group received more antibiotic therapy than those in the mild disease group.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33120785" target="_blank">33120785</a>
</td>
<td style="text-align:center;">
Intravenous immunoglobulin, oseltamivir, and ribavirin were associated with reduced mortality in normal weight patients.Overweight is a worldwide health problem.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33128482" target="_blank">33128482</a>
</td>
<td style="text-align:center;">
Presently, several drugs, such as hydroxychloroquine, ribavirin, favipiravir (FVP), lopinavir/ritonavir (LPV/r), remdesivir and oseltamivir, have been suggested as effective treatments for SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33130195" target="_blank">33130195</a>
</td>
<td style="text-align:center;">
On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33137493" target="_blank">33137493</a>
</td>
<td style="text-align:center;">
Ivermectin, azithromycin and oseltamivir did not substantially reduce risk further.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33145132" target="_blank">33145132</a>
</td>
<td style="text-align:center;">
He received parenteral meropenem and oral oseltamivir with parenteral methylprednisolone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33173052" target="_blank">33173052</a>
</td>
<td style="text-align:center;">
Drug enrichment analysis of dysregulated genes has allowed us to propose novel therapies, including lung surfactants, respiratory stimulants, sargramostim, and oseltamivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33186512" target="_blank">33186512</a>
</td>
<td style="text-align:center;">
Treatment included immunoglobulin (89%); corticosteroids, antibiotics, and enoxaparin in about 50%; and oseltamivir and antifungal therapy in less than 10%.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33190342" target="_blank">33190342</a>
</td>
<td style="text-align:center;">
In addition, 64.8% of the patients had received azithromycin, 59.4% of the patients had received oseltamivir, and hydroxychloroquine was used in combination with azithromycin in 35.1% of the children.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33190802" target="_blank">33190802</a>
</td>
<td style="text-align:center;">
With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir, oseltamivir, nitazoxanide, nelfinavir, and camostat mesylate, has been increasing.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33191206" target="_blank">33191206</a>
</td>
<td style="text-align:center;">
These drugs include fingolimod, colchicine, N4-hydroxycytidine, remdesivir, methylprednisone, oseltamivir, icatibant, perphanizine, viracept, emetine, homoharringtonine, aloxistatin, ribavirin, valrubicin, famotidine, almitrine, amprenavir, hesperidin, biorobin, cromolyn sodium, and antibodies- tocilzumab and sarilumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33213130" target="_blank">33213130</a>
</td>
<td style="text-align:center;">
In addition to supportive care, lopinavir/ritonavir 400/100 mg twice daily and oseltamivir (75 mg) twice daily were started in combination with a starting dose of hydroxychloroquine (400 mg).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33218161" target="_blank">33218161</a>
</td>
<td style="text-align:center;">
Lopinavir/ritonavir, hydroxychloroquine, antibiotics, ribavirin, oseltamivir, and interferon were administered to 35.8%, 28.4%, 38.1%, 0.1%, 0.3%, and 0.9% of patients, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33219182" target="_blank">33219182</a>
</td>
<td style="text-align:center;">
Oseltamivir, Ribavirin in patients with COVID-19; but none of which showed efficacy of antiviral therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33240733" target="_blank">33240733</a>
</td>
<td style="text-align:center;">
The rash started after he took azithromycin, oseltamivir, ribavirin, lopinavir, hydroxychloroquine, prednisolone, ceftriaxone, clindamycin, interferon (IFN) beta, and ceftazidime for COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33250495" target="_blank">33250495</a>
</td>
<td style="text-align:center;">
Out of 156 children, 78 (50%) children received Hydroxychloroquine-containing regimen, 15 of them were treated with hydroxychloroquine + azithromycin + oseltamivir, 44 were treated with hydroxychloroquine + azithromycin and 21 were only treated with hydroxychloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33257051" target="_blank">33257051</a>
</td>
<td style="text-align:center;">
Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33261071" target="_blank">33261071</a>
</td>
<td style="text-align:center;">
Oseltamivir phosphate (OP) is an antiviral drug available only as oral therapy for the treatment of influenza and as a potential treatment option when in combination with other medication in the fight against the corona virus disease (COVID-19) pneumonia.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33275961" target="_blank">33275961</a>
</td>
<td style="text-align:center;">
Here in the present study, we integrated the high throughput computational screening and dynamic simulation approach to identify the most promising candidate lead compound against NSP15.5-fluoro-2-oxo-1H-pyrazine-3-carboxamide (favipiravir), (3R,4R, 5R)-3,4-Bis(benzyloxy)-5-((benzyloxy) methyl) dihydrofuran-2(3H)-one) remedesivir, 1,3-thiazol-5-ylmethyl N-[(2S,3S, 5S)-3-hydroxy-5-[[(2 S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate (ritonavir), ethyl (3R,4R, 5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate (oseltamivir), and (2 S)-N-[(2S,4S, 5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide (lopinavir) were chosen as a training set to generate the pharmacophore model.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33290969" target="_blank">33290969</a>
</td>
<td style="text-align:center;">
Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33296027" target="_blank">33296027</a>
</td>
<td style="text-align:center;">
The effectiveness of oseltamivir on COVID-19 suspected outpatients without hypoxia was evaluated. […] All patients received antiviral therapy (oseltamivir) and antibacterial therapy together. […] Oseltamivir administration made the temperature fall within 24 h in part (10, 63%). […] Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 h, and patients administered late treatment (LT), initiated after this time point. […] These findings suggest that early oseltamivir administration may lower the duration of fever in COVID-19 suspected outpatients without hypoxia when it is used in combination with antibacterial therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33297919" target="_blank">33297919</a>
</td>
<td style="text-align:center;">
She received a single dose of hydroxychloroquine 400 mg, Oseltamivir 75 mg every 12 hours, lopinavir/ritonavir (Kaletra) 400/100 mg every 12 hours, and levofloxacin 750 mg daily.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33309013" target="_blank">33309013</a>
</td>
<td style="text-align:center;">
A COVID-19 test was positive, and hydroxychloroquine, oseltamivir, baclofen, and symptomatic treatment were initiated.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33330784" target="_blank">33330784</a>
</td>
<td style="text-align:center;">
The drugs utilized in more than one trials were remdesivir (6 trials), lopinavir/ritonavir (6 trials), hydroxychloroquine (6 trials), interferon (5 trials), methylprednisolone (3 trials), nitric oxide gas (3 trials), oseltamivir (2 trials), arbidol (2 trials), and vitamin C (2 trials).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33333102" target="_blank">33333102</a>
</td>
<td style="text-align:center;">
Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. […] The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. […] The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. […] Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33352097" target="_blank">33352097</a>
</td>
<td style="text-align:center;">
Besides the supportive treatment, most commonly used agents are immunomodulatory drugs such as plaquenil and azitromycin, and anti-virals including oseltamivir, ritonavir-lopinavir, favipiravir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33412996" target="_blank">33412996</a>
</td>
<td style="text-align:center;">
Abigail (80.9%), ribavirin (36.6%), oseltamivir (38.9%), interferon (16.4%), and ganciclovir (14.5%) were used for the anti-viral treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33441085" target="_blank">33441085</a>
</td>
<td style="text-align:center;">
He was admitted to the biocontainment unit of Nebraska Medicine for concerns of possible COVID-19 and was started on oseltamivir for influenza and vancomycin/cefepime for the probable bacterial cause of his pneumonia and diarrhea.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33451758" target="_blank">33451758</a>
</td>
<td style="text-align:center;">
The first patient was a 30-year-old man who, despite being treated with hydroxychloroquine, favipiravir, oseltamivir, and azithromycin therapy, died because of the presence of other comorbidities.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33458647" target="_blank">33458647</a>
</td>
<td style="text-align:center;">
Many promising antiviral agents including lopinavir, ritonavir, remdesivir, umifenovir, darunavir, and oseltamivir have been repurposed and are currently trialled in the care for COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33477522" target="_blank">33477522</a>
</td>
<td style="text-align:center;">
Most of therapeutic options considered for SARS-CoV-2 treatment (e.g., lopinavir/ritonavir, oseltamivir, hydroxychloroquine, azithromycin, tocilizumab, and convalescent plasma) failed to confirm significant efficiency.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33522466" target="_blank">33522466</a>
</td>
<td style="text-align:center;">
The outpatient treatment was started on the first day and included an antiviral therapy (oseltamivir), mucolytics (bromhexine), vitamin C, and anticoagulants.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33542445" target="_blank">33542445</a>
</td>
<td style="text-align:center;">
These drugs include chloroquine (CQ), hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir (LPV/r), atazanavir (ATV), favipiravir (FVP), nevirapine (NVP), efavirenz (EFV), oseltamivir, remdesivir, anakinra, tocilizumab (TCZ), eculizumab, heme oxygenase 1 (HO-1) regulators, renin-angiotensin-aldosterone system (RAAS) inhibitors, ivermectin, and nitazoxanide. […] The major drug variant pairs that associated with variations in clinical efficacy include CQ/HCQ (CYP2C8, CYP2D6, ACE2, and HO-1); azithromycin (ABCB1); LPV/r (SLCO1B1, ABCB1, ABCC2 and CYP3A); NVP (ABCC10); oseltamivir (CES1 and ABCB1); remdesivir (CYP2C8, CYP2D6, CYP3A4, and OATP1B1); anakinra (IL-1a); and TCZ (IL6R and FCGR3A).
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
